Why it died
Montedison was a sprawling conglomerate that tried to be everything from agriculture to industrial chemicals, and the sprawl is what sank it. The version that works now is the opposite of a conglomerate: one high-value specialty material, sold to one industry that cannot easily switch.
How you would build it now
You would not build Montedison's giant plants. Specialty chemistry is now an asset-light business if you design it that way. Formulate and prove the compound in a rented lab or a university partnership, then run production through a contract manufacturer, a network of toll and custom-synthesis shops that will make your material to spec without you owning a single reactor. That turns a billion-dollar capital problem into a per-batch cost.
The hard part is no longer chemistry, it is regulation and trust, and modern tooling helps there too. Regulatory consultants and software handle REACH and EPA filings that once took an internal department. Selling is narrow and technical: identify the twenty companies that need this exact material, reach the right engineers directly through LinkedIn and industry channels, and win on spec sheets and samples rather than a sales force. One defensible compound with the approvals to sell it is a business a small team can hold.
- Development: a rented lab or university research partnership
- Production: contract and toll manufacturers, no owned plant
- Compliance: regulatory consultants plus filing software
- Sales: direct technical outreach to a named list of buyers
- Moat: patents and hard-won regulatory approvals
The verdict
The conglomerate is a dead form. The focused, asset-light materials company underneath it is very much alive, and more reachable than it looks if you go narrow and technical.
← All issues